The European Consortium for the Study of Topical Treatment of Neovascular Glaucoma– the STRONG Study, is an FP7 funded consortium to assess the efficacy of a topical anti-angiogenic agent in the treatment of Neovascular Glaucoma secondary to ischemic CRVO.
Coordinated by the department of Ophthalmology of the University Eye Hospital in Mainz, Germany, the STRONG Study is a Phase II/III randomised, double-masked, 3-group, placebo-controlled trial to assess the efficacy of Aganirsen antisense oligonucleotide in reducing the rate of iris neovascularisation and NVG development after ischemic CRVO. Aganirsen is an antisense oligonucleotide inhibiting IRS-1 in pro-angiogenic conditions developed by Gene Signal, a research and development based biotechnology company focused on developing drugs for the regulation of angiogenesis.
The present message aims at updating the medical research community about the STRONG project (European Consortium for the Study of a Topical Treatment of iCRVO to prevent Neovascular Glaucoma – the STRONG Study), a clinical trial supported in part by the European Commission, launched in October 2012 following its selection for funding by European experts.
Read more »